Enanta Pharmaceuticals, the Massachusetts-based biotech focused on developing drugs to fight hepatitis C and MRSA infections, relies on long-time PR firm as it plans initial public offering.

Full Story | Subscribe to O'Dwyer's | Free E-Newsletter on PR